拉斯维加斯Nevada肿瘤研究所白血病干细胞博士后岗位
来源：丁香人才网
日期：2008-01-02
Institution
Nevada Cancer Institute
Position
Postdoctoral Position
Location
Las Vegas, NV
Date Posted
Dec 28th 2007
Description
Two federal-funded postdoctoral positions are available immediately forhighly motivated individuals at the Nevada Cancer Institute in LasVegas. We are studying how pluripotency of human embryonic and adultstem cells maintains and how its deregulation may result in cancer stemcells with a focus on leukemic stem cells. A Ph.D. degree with strongbackground in molecular biology, biochemistry, and tissue culture ishigh desirable. Prior experience in hematopoietic stem cells or humanembryonic stem cells is required.
Recent publications from the laboratory:
1. L Chai, Yang J, Di C, Cui W, Lai R, and Ma Y. Transcriptionalactivation of the SALL1 by the human SIX1 domain. 2006, J. Biol. Chem. 14;281(28):18918-26.
2. Ma Y, Wei C, Yang J, Qu J, Di C , Amin HM, Lai R, Ritz J, Krause DS,and L Chai. SALL4, a novel oncogene, is constitutively expressed inacute myeloid leukemia (AML) and is sufficient to induce AML intransgenic mice. 2006, Blood, Oct 15;108(8):2726-35.
3. Zhang J, Tam W, Tong GQ, Wu Q, Chan BS, Lou Y, Yang J, Ma Y, Chai L,Ng H, Lufkin T, Robson P and B Lim. Sall4 modulates embryonic stem cellpluripotency and early embryonic development by the transcriptionalregulation of Pou5f1. 2006, Nature Cell Biology, Oct;8(10): 1114.
4. Yang J, Chai L, Liu F, Flink L, Pei L, Siberstain L, Amin, HM, WardD, and Ma Y. Bmi-1 is a SALL4 Target Gene for SALL4 in Hematopoietic andLeukemic Cells. 2007, Proc. Natl. Acad. Sci. USA. 2007;104:10494-10499.
Contact
Please send curriculum vitae and names and contact information of threereferences to: Yupo Ma, MD, PhD, Chief of Hematopathology at NevadaCancer Institute, yma@nvcancer.org
Nevada Cancer Institute
Position
Postdoctoral Position
Location
Las Vegas, NV
Date Posted
Dec 28th 2007
Description
Two federal-funded postdoctoral positions are available immediately forhighly motivated individuals at the Nevada Cancer Institute in LasVegas. We are studying how pluripotency of human embryonic and adultstem cells maintains and how its deregulation may result in cancer stemcells with a focus on leukemic stem cells. A Ph.D. degree with strongbackground in molecular biology, biochemistry, and tissue culture ishigh desirable. Prior experience in hematopoietic stem cells or humanembryonic stem cells is required.
Recent publications from the laboratory:
1. L Chai, Yang J, Di C, Cui W, Lai R, and Ma Y. Transcriptionalactivation of the SALL1 by the human SIX1 domain. 2006, J. Biol. Chem. 14;281(28):18918-26.
2. Ma Y, Wei C, Yang J, Qu J, Di C , Amin HM, Lai R, Ritz J, Krause DS,and L Chai. SALL4, a novel oncogene, is constitutively expressed inacute myeloid leukemia (AML) and is sufficient to induce AML intransgenic mice. 2006, Blood, Oct 15;108(8):2726-35.
3. Zhang J, Tam W, Tong GQ, Wu Q, Chan BS, Lou Y, Yang J, Ma Y, Chai L,Ng H, Lufkin T, Robson P and B Lim. Sall4 modulates embryonic stem cellpluripotency and early embryonic development by the transcriptionalregulation of Pou5f1. 2006, Nature Cell Biology, Oct;8(10): 1114.
4. Yang J, Chai L, Liu F, Flink L, Pei L, Siberstain L, Amin, HM, WardD, and Ma Y. Bmi-1 is a SALL4 Target Gene for SALL4 in Hematopoietic andLeukemic Cells. 2007, Proc. Natl. Acad. Sci. USA. 2007;104:10494-10499.
Contact
Please send curriculum vitae and names and contact information of threereferences to: Yupo Ma, MD, PhD, Chief of Hematopathology at NevadaCancer Institute, yma@nvcancer.org
[作者：jurgen 编辑：]